-

GE HealthCare unveils enhanced Voluson Expert Series women’s health ultrasound systems with focus on early detection and exam efficiency

  • Latest Voluson Expert 22, 20 and 18 ultrasound systems harness artificial intelligence and advanced tools and software for more efficient assessments
  • Voluson Expert Series delivers elevated performance, with focus on first trimester to reveal clearer anatomical details, aiding earlier detection and boosting diagnostic confidence

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the updated portfolio of Voluson™ Expert Series ultrasound systems. Voluson Expert 22, 20 and 18 combine high resolution image quality with advanced ultrasound technology and an ergonomic design for efficient workflow and a world-class user experience. The Voluson Expert Series integrates artificial intelligence (AI)-powered features and automation tools to help drive imaging performance and efficiencies in women’s healthcare.

Approximately 30,000 to 50,000 women in the United States experience complex, high-risk pregnancy each year.i When these complications are left undetected or untreated, it may harm the mother or the baby. The growing prevalence of these complicationsii underscores the need for innovative solutions that enable early detection and intervention.

The Voluson Expert Series, GE HealthCare’s most advanced women’s health ultrasound systems, offers premium ultrasound imaging for confident diagnoses for high risk, complex pregnancies. The Lyric Architecture is designed to unlock new imaging and processing power to deliver detailed and uniform images and reveal finer details within the anatomy with ease, even in difficult scanning conditions. AI-enabled functionality and automation tools are available to support faster assessments and early detection, diagnosis and intervention.

The SonoLyst suite of AI tools were designed to simplify exams through image recognition and automated annotations and measurements, increasing exam speed and accuracy. With this new release, clinicians can now utilize SonoLystlive during 11 to 14-week anatomical exams helping ensure required views are captured for diagnostic accuracy.  In addition, Voluson Expert Series ultrasound systems feature an expanded color Doppler offering, Graphicflow, which provides a graphical representation of the trajectories of the blood cells in real-time to visualize complex blood flow quickly and clearly, helping users differentiate normal from abnormal hemodynamics.

Voluson Expert Series also includes additional enhancements to select Voluson AI tools:

  • SonoPelvicFloor3.0 can help reduce pelvic floor measurement exam time by 80%.* This feature now expands anatomical views, and simplifies the exam process by automating plane alignment, live C-plane tracking, and measurements.
  • SonoAVCfollicle2.0 uses AI to increase accuracy and precision in follicle detection, resulting in a better success rate of detecting follicles, along with reduced artifacts and requiring less time for postprocessing.

These systems are compatible with a wide selection of unique specialty probes, including a new lightweight 2D/3D probe RAB7-D, and wireless Vscan Air™ dual probes.

“We are proud to introduce these updates to the Voluson Expert ultrasound systems, which represent our ongoing commitment to advancing technology that addresses women's health needs of today, and the future,” said Gerald Seifriedsberger, General Manager, Women’s Health, Advanced Visualization Solutions, GE HealthCare. “By introducing solutions that offer unparalleled clarity and detail, we can empower users with critical insights for informed care decisions and efficient exams, transforming how clinicians approach healthcare. Together, we can create a healthier future for all women.”

GE HealthCare will showcase the Voluson Expert series ultrasound systems at the Society for Maternal-Fetal Medicine (SMFM) 2025 Pregnancy Meeting™ taking place on January 27-February 1 in Denver. The Voluson Expert Series is available in the United States. For more information on the Voluson Expert Series, visit: https://www.gehealthcare.com/products/ultrasound/voluson.

*Versus manual exam

___________________________________

i Cleveland Clinic. High-Risk Pregnancy. Cleveland Clinic. https://my.clevelandclinic.org/health/diseases/22190-high-risk-pregnancy. Last reviewed July 12, 2024. Accessed January 17, 2025.

ii Barfield WD, Besera G, Cox S, Warner L, Azeez O, Riggs J, Russell R, Bowron S, Churchill RE. From Data to Action: CDC's Public Health Surveillance for Women, Infants, and Children. 2nd ed. Centers for Disease Control and Prevention; 2020. https://www.cdc.gov/reproductive-health/media/pdfs/data-to-action/Data-To-Action_508.pdf. Accessed January 17, 2025.

 

Contacts

Eric Tatro
Media Contact
GE HealthCare
+1 312 459 6140
Eric.Tatro@gehealthcare.com

GE HealthCare

NASDAQ:GEHC

Release Versions

Contacts

Eric Tatro
Media Contact
GE HealthCare
+1 312 459 6140
Eric.Tatro@gehealthcare.com

More News From GE HealthCare

GE HealthCare announces lead industrial role in largest EU-funded IHI consortium to advance cardio-oncology care across Europe

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced its leading industrial role in the new COMPASS consortium, a five-year initiative focused on improving precision cardio-oncology care and advancing early detection of cardiovascular risks in cancer patients across Europe. COMPASS combines clinical excellence with novel healthcare technology, and with a total budget of €50.5 million and more than sixty partners, it is one of the largest public-private partnerships under the I...

GE HealthCare to showcase comprehensive cardiology portfolio at ACC.26, including its latest AI-enabled imaging technologies, advanced software solutions, and key collaborations

CHICAGO--(BUSINESS WIRE)--At ACC.26, GE HealthCare (Nasdaq: GEHC) will showcase some of its boldest ideas yet that support clinicians across the cardiology care pathway - from diagnosis to treatment to procedural guidance and monitoring. Its latest cardiology innovations, featuring advancements within diagnostic cardiology, CT, image guiding solutions, ultrasound, cloud, and software solutions, are helping clinicians deliver critical precision care throughout the patient journey. According to t...

GE HealthCare’s Photonova Spectra photon-counting CT receives FDA clearance

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Photonova™ Spectra,i an innovative photon‑counting computed tomography (PCCT) solution powered by the company’s novel Deep Silicon detector technology and offered as a flexible platform with multiple configurations to meet diverse clinical needs. With wide coverage and the combination of ultra-high definition (UHD) spatial and spectral imaging, Photonova Spec...
Back to Newsroom